

# Nathan Perlis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7783519/publications.pdf>

Version: 2024-02-01

61  
papers

711  
citations

471061

17  
h-index

610482

24  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1140  
citing authors

#	ARTICLE	IF	CITATIONS
1	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. <i>European Urology</i> , 2021, 80, 374-382.	0.9	49
2	Smarter screening for prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 991-999.	1.2	44
3	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 203, 1085-1093.	0.2	44
4	Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. <i>Journal of Urology</i> , 2018, 200, 104-113.	0.2	41
5	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. <i>Journal of Urology</i> , 2017, 197, 75-83.	0.2	39
6	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , 2021, 300, 369-379.	3.6	34
7	Evaluating potential live-renal donors: Causes for rejection, deferral and planned procedure type, a single-centre experience. <i>Canadian Urological Association Journal</i> , 2013, 7, 41.	0.3	33
8	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. <i>Radiology</i> , 2021, 298, 695-703.	3.6	33
9	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer – phase 1 trial. <i>European Radiology</i> , 2018, 28, 4281-4287.	2.3	30
10	Can video games enhance surgical skills acquisition for medical students? A systematic review. <i>Surgery</i> , 2021, 169, 821-829.	1.0	29
11	Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. <i>World Journal of Urology</i> , 2013, 31, 161-167.	1.2	28
12	Coital frequency and infertility: which male factors predict less frequent coitus among infertile couples?. <i>Fertility and Sterility</i> , 2013, 100, 511-515.	0.5	25
13	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. <i>BJU International</i> , 2017, 120, 76-82.	1.3	23
14	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , 2018, 199, 1182-1187.	0.2	22
15	The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer. <i>Journal of Urology</i> , 2018, 200, 283-291.	0.2	22
16	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. <i>BJU International</i> , 2020, 125, 525-530.	1.3	21
17	Contemporary Active Surveillance. <i>Urologic Clinics of North America</i> , 2017, 44, 565-574.	0.8	20
18	Conceptualizing global health-related quality of life in bladder cancer. <i>Quality of Life Research</i> , 2014, 23, 2153-2167.	1.5	16

#	ARTICLE	IF	CITATIONS
19	Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3702-3711.	3.3	15
20	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. <i>European Urology Open Science</i> , 2020, 22, 61-73.	0.2	11
21	Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer. <i>British Journal of Radiology</i> , 2022, 95, 20210414.	1.0	11
22	Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. <i>European Urology Focus</i> , 2021, 7, 582-588.	1.6	10
23	A Prospective Randomized Controlled Trial of Irrigation "Bag Squeeze" to Manage Pain for Patients Undergoing Flexible Cystoscopy. <i>Journal of Urology</i> , 2020, 204, 1012-1018.	0.2	9
24	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. <i>Journal of Urology</i> , 2020, 204, 1187-1194.	0.2	9
25	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. <i>European Radiology</i> , 2022, 32, 7544-7554.	2.3	8
26	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives. <i>Canadian Urological Association Journal</i> , 2018, 12, E210-8.	0.3	7
27	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 88-96.	2.6	7
28	Population-based outcomes of men with a single negative prostate biopsy: Importance of continued follow-up among older patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 298.e19-298.e27.	0.8	7
29	Sexual function and rehabilitation after radiation therapy for prostate cancer: a review. <i>International Journal of Impotence Research</i> , 2021, 33, 410-417.	1.0	7
30	Creating patient-centered radiology reports to empower patients undergoing prostate magnetic resonance imaging. <i>Canadian Urological Association Journal</i> , 2020, 15, 108-113.	0.3	7
31	<sup>18</sup> F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1615-1620.	2.8	4
32	Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study. <i>BJU International</i> , 2021, 128, 615-624.	1.3	4
33	Salvage interstitial laser thermal therapy under MRI guidance (MRgFLA) for high-intensity focal ultrasound (HIFU) recurrences: feasibility study. <i>Clinical Imaging</i> , 2021, 76, 217-221.	0.8	4
34	Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with synchro or metachronous metastatic disease. <i>Prostate</i> , 2022, 82, 345-351.	1.2	4
35	"Bring the Hoses to Where the Fire Is": Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs. <i>Value in Health</i> , 2022, 25, 1307-1316.	0.1	4
36	Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice. <i>Journal of Urology</i> , 2018, 199, 251-256.	0.2	3

#	ARTICLE	IF	CITATIONS
37	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. Canadian Urological Association Journal, 2018, 13, 250-255.	0.3	3
38	What are the limits of focal therapy for localized prostate cancer? For: GG3-5 may be considered. European Urology Focus, 2020, 6, 201-202.	1.6	3
39	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.3	3
40	Case â€ Reflex anuria: A rare complication of retrograde pyelography. Canadian Urological Association Journal, 2020, 15, E380-E382.	0.3	3
41	Case â€ Foamy high-grade prostatic intraepithelial neoplasia: A false positive for prostate cancer on multiparametric magnetic resonance imaging?. Canadian Urological Association Journal, 2018, 12, E256-9.	0.3	2
42	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. Journal of Urology, 2018, 200, 1056-1061.	0.2	2
43	Predictors of prostate-specific antigen testing in men aged â‰¥55 years: A cross-sectional study based on patient-reported outcomes. International Journal of Urology, 2020, 27, 711-718.	0.5	2
44	How I Do It - MRI-ultrasound fusion prostate biopsy using the Fusion MR and Fusion Bx systems. Canadian Journal of Urology, 2020, 27, 10185-10191.	0.0	2
45	Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction. Journal of Endourology, 2022, 36, 1083-1090.	1.1	2
46	Exploring the value of using patient-oriented MRI reports in clinical practice â€ a pilot study. Supportive Care in Cancer, 2022, 30, 6857-6876.	1.0	2
47	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. European Urology Open Science, 2020, 21, 1-4.	0.2	1
48	Diagnostic utility of axial imaging in the evaluation of hematuria: A systematic review and critical appraisal of the literature. Canadian Urological Association Journal, 2020, 15, 48-55.	0.3	1
49	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (<sup>18</sup>F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5553-5553.	0.8	1
50	Editorial Comment. Journal of Urology, 2017, 197, 1013-1013.	0.2	0
51	Editorial Comment. Journal of Urology, 2021, 205, 1098-1099.	0.2	0
52	Editorial Comment. Journal of Urology, 2019, 201, 82-82.	0.2	0
53	Editorial Comment. Journal of Urology, 2019, 201, 320-321.	0.2	0
54	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Reply by Authors. Journal of Urology, 2020, 204, 1194-1194.	0.2	0
56	Editorial Comment. Journal of Urology, 2020, 203, 329-329.	0.2	0
57	Target prostate biopsies: how best to report in synoptic format?. Canadian Urological Association Journal, 2021, 16, .	0.3	0
58	Editorial Comment. Journal of Urology, 2021, , 101097JU0000000000000220501.	0.2	0
59	The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.. Journal of Clinical Oncology, 2022, 40, 333-333.	0.8	0
60	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. Journal of Clinical Oncology, 2022, 40, 332-332.	0.8	0
61	Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0